Roxadustat

Phase II Trials

Also known as: FG-4592, Evrenzo, Aibisi

Prescription Only — FDA Approved Medication

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in multiple countries including China, Japan, and the EU for the management of anemia associated with chronic kidney disease. It stimulates endogenous erythropoietin production by stabilizing HIF-alpha proteins.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

Muscle Recovery & Repair
Cardiovascular Health

Mechanism of Action

Inhibits HIF prolyl hydroxylase domain (PHD) enzymes, preventing hydroxylation and proteasomal degradation of HIF-1alpha and HIF-2alpha. Stabilized HIF-alpha enters the nucleus, upregulating erythropoietin production and iron absorption/utilization genes.

Safety Notes

Approved in China, Japan, EU, UK, and other countries. The FDA issued a Complete Response Letter citing cardiovascular safety concerns. Associated with increased risk of cardiovascular events and thrombosis in some trial arms.

Want to learn more?

Ask Research Chat about Roxadustat

Research Profile

Half-Life

~12-16 hours

Administration

oral

Legal Status (US)

Approved in China, Japan, EU, and UK. Not FDA-approved in the US as of 2024. Prescription medication where approved.

303 indexed research passages

Related Peptides

Tropisetron

Tropisetron is a 5-HT3 receptor antagonist and alpha7 nicotinic acetylcholine receptor agonist approved in various countries for chemotherapy-induced nausea. Research has also examined its potential roles in pain management, fibromyalgia, and cognitive enhancement through its dual receptor pharmacology.

GHRP-2

GHRP-2 (pralmorelin) is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate pulsatile GH release through the ghrelin receptor. It has been investigated in clinical studies and is sometimes used diagnostically for growth hormone deficiency assessment in some countries.

Hexarelin

Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate GH release and its potential cardioprotective effects in animal models and early human studies.

KPV

KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research has examined its potent anti-inflammatory properties, particularly in gut epithelial models and inflammatory bowel disease research.